Google DeepMind Launches AlphaGenome 2 to Unravel Cellular Roots of Disease
Researchers at Google DeepMind have unveiled AlphaGenome 2, a next-generation AI model designed to predict how genetic variants affect specific human cell types and states. Serving as the successor to the original AlphaGenome, the new model bridges single-cell biology and human genetics. Trained on over 100 million individual cell profiles across 68 tissues, AlphaGenome 2 provides scientists with a detailed view of how changes in DNA impact cell-specific gene expression. This capability helps uncover cellular drivers of disease that are often missed by broad-tissue models, pointing the way toward new treatments and offering enhanced variant predictive performance for non-commercial research via the AlphaGenome API.
Key Takeaways
- Google DeepMind has introduced AlphaGenome 2, a next-generation DNA sequence model bridging single-cell biology and human genetics.
- The model is trained on more than 100 million individual cell profiles across 68 tissues to predict how genetic variants impact specific human cell types and states.
- AlphaGenome 2 identifies nearly twice as many variants that change gene expression in cells compared to the previous state-of-the-art model.
- The tool is designed to help researchers uncover cellular root causes of disease and is made available for non-commercial research through the AlphaGenome API.
In-Depth Analysis
Bridging Single-Cell Biology and Human Genetics
Researchers at Google DeepMind developed AlphaGenome 2 to tackle a notoriously difficult problem in genetics: understanding how subtle DNA variations affect gene expression across different cells. Every cell in the human body carries the same DNA blueprint, yet distinct cell types and states—such as a heart muscle cell or an immune cell—switch different genes on or off to perform their specific functions. While global initiatives like the Human Cell Atlas map gene expression for millions of cells, predicting how subtle DNA variations alter this expression has remained an unsolved challenge. AlphaGenome 2 addresses this by zooming in from broad tissue averages to individual cell types and cell states.
Architectural Improvements and Enhanced Predictive Performance
By redesigning the model's architecture and training it on extensive data including over 100 million individual cell profiles across 68 tissues, AlphaGenome 2 achieves a step-change improvement in variant predictive performance. Unlike broad-tissue models, this conditional model structure allows researchers to predict variant effects in disease-relevant cells that would otherwise be missed. Furthermore, it enables predictions for cell and disease states that the model has not encountered during training, identifying nearly twice as many variants that alter gene expression in cells compared to DeepMind's previous model.
Industry Impact
The introduction of AlphaGenome 2 represents a major milestone for computational genomics and disease research. By turning static cell atlases into predictive engines, the tool helps scientists prioritize and interpret variant effects in rare diseases, complex traits, and fundamental biology. Providing access to non-commercial researchers through the AlphaGenome API accelerates the path toward uncovering the cellular drivers of disease and developing targeted medical treatments.
Frequently Asked Questions
Question
What is AlphaGenome 2?
Answer
AlphaGenome 2 is a next-generation DNA sequence AI model developed by Google DeepMind that predicts how DNA sequences and their variations impact specific human cell types and cell states.
Question
How was AlphaGenome 2 trained?
Answer
The model was trained on more than 100 million individual cell profiles across 68 tissues, allowing it to bridge single-cell biology and human genetics.
Question
How can researchers access AlphaGenome 2?
Answer
Google DeepMind makes AlphaGenome 2 available for non-commercial research through the AlphaGenome API.
